Related Content
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology has ...
October 12, 2018 β Reva Medical presented four key data sets demonstrating the capabilities of the companyβs Fantom ...
November 7, 2016 β The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3 ...
June 5, 2015 - REVA Medical Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its ...
February 12, 2015 β A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The ...
December 31, 2014 β Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. The ...
(UPDATE: read the Sept. 8, 2017 article "Abbott Will End Sales of Absorb Bioresorbable Stent") A key prediction for ...
January 23, 2014 β An implant of the ReZolve2 bioresorbable scaffold was transmitted live via satellite at the ...
April 2, 2013 β Reva Medical Inc. announced that it has initiated patient enrollment into a clinical trial with its ...
July 16, 2012 β Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting bioresorbable ...